Therapeutic angiogenesis in treatment of chronic lower-limb ischemia: possibilities of using gene therapy. Consensus of Russian experts
AbstractTherapeutic angiogenesis is a method of inducing neovascularization in ischemized tissues. The consensus of Russian experts presents the relevant information on the history and state of the art of using the method of therapeutic angiogenesis in vascular surgery, particularly the possibilities of gene engineering on the example of the only registered in the Russian Federation drug containing in its composition plasmid supercoiled deoxyribonucleic acid carrying the gene encoding vascular endothelial growth factor under control of promoter pCMV‑VEGF165. The current consensus determines the place of gene therapeutic angiogenesis in treatment of patients with occlusive lesions of lower-limb vessels from the position of evidence-based medicine.
Keywords: therapeutic angiogenesis; gene therapy; lower-limb chronic ischemia; pCMV VEGF165; VEGF 165; Neovasculogen®
Funding. The study had no financial support.
Conflict of interest. The authors declare no conflict of interest.
Authors’ contribution. Concept and design of the study – Gavrilenko A.V., Chupin A.V., Suchkov I.A.; collection and processing of material – Mzhavanadze N.D., Zholkovsky A.V., Chervyakov Yu.V., Pinchuk O.V., Svetlikov А.V., Fokin A.A., Gavrilenko A.V., Chupin A.V., Suchkov I.A.; writing the text – Mzhavanadze N.D., Suchkov I.A., Chervyakov Yu.V.; editing – Gavrilenko A.V., Chupin A.V., Suchkov I.A.
For citation: Gavrilenko A.V., Chupin A.V., Mzhavanadze N.D., Zholkovsky A.V., Pinchuk O.V., Svetlikov A.V., Fokin A.A., Chervyakov Yu.V., Suchkov I.A. Therapeutic angiogenesis in treatment of chronic lower-limb ischemia: possibilities of using gene therapy. Consensus of Russian experts. Angiology and Vascular Surgery. Journal named after Academician A.V. Pokrovsky. 2025; 31 (3): 8–15. DOI: https://doi.org/10.33029/1027-6661-2025-31-3-8-15
Dear readers!
Full-text version of the article is available only in paper version.